Skip to main content
Top
Published in: Clinical Rheumatology 8/2016

01-08-2016 | Original Article

Elevated high-mobility group B1 levels in active adult-onset Still’s disease associated with systemic score and skin rash

Authors: Ju-Yang Jung, Chang-Hee Suh, Seonghyang Sohn, Jin-Young Nam, Hyoun-Ah Kim

Published in: Clinical Rheumatology | Issue 8/2016

Login to get access

Abstract

High-mobility group box-1 (HMGB1) is a nuclear protein, and such prototypical damage-associated molecular patterns mediate the immune response in the noninfectious inflammatory response. Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder involved in the dysregulation of innate immunity. We investigated the serum HMGB1 level in patients with AOSD and evaluated its clinical significance. Blood samples were collected from 40 patients with active AOSD and 40 healthy controls (HC). Of the patients with AOSD, follow-up samples were collected from 16 patients after a resolution of AOSD disease activity. Serum HMGB1 levels in patients with AOSD were higher than those of the HC (10.0 ± 5.85 vs. 5.15 ± 1.79 ng/mL, p < 0.001). Serum HMGB1 levels were found to be correlated with C-reactive protein (CRP) and the systemic score. The AOSD patient who had a sore throat showed a higher serum HMGB1 level than those patients who did not, and the patient with a skin rash had higher levels than the patients without. In addition, the serum HMGB1 levels were decreased after the resolution of disease activity in the AOSD patients who were followed up. The serum HMGB1 levels were elevated in AOSD patients compared to the HC and were correlated with both CRP and the systemic score. The HMGB1 levels were associated with skin rash and a sore throat in AOSD patients. After the resolution of disease activity, serum HMGB1 levels were found to have decreased.
Literature
2.
go back to reference Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Akizuki M et al (1990) Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol 17:1058–1063PubMed Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Akizuki M et al (1990) Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol 17:1058–1063PubMed
3.
go back to reference Kim HA, Sung JM, Suh CH (2012) Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int 32:1291–1298CrossRefPubMed Kim HA, Sung JM, Suh CH (2012) Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int 32:1291–1298CrossRefPubMed
4.
go back to reference Efthimiou P, Kontzias A, Ward CM, Ogden NS (2007) Adult-onset Still’s disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 3:328–335CrossRefPubMed Efthimiou P, Kontzias A, Ward CM, Ogden NS (2007) Adult-onset Still’s disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 3:328–335CrossRefPubMed
5.
go back to reference Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P (2014) Adult-onset Still’s disease. Autoimmun Rev 13:708–722CrossRefPubMed Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P (2014) Adult-onset Still’s disease. Autoimmun Rev 13:708–722CrossRefPubMed
6.
go back to reference Kim HA, Kwon JE, Yim H, Suh CH, Jung JY, Han JH (2015) The pathologic findings of skin, lymph node, liver, and bone marrow in patients with adult-onset still disease: a comprehensive analysis of 40 cases. Medicine (Baltimore) 94:e787CrossRef Kim HA, Kwon JE, Yim H, Suh CH, Jung JY, Han JH (2015) The pathologic findings of skin, lymph node, liver, and bone marrow in patients with adult-onset still disease: a comprehensive analysis of 40 cases. Medicine (Baltimore) 94:e787CrossRef
7.
go back to reference Kumar S, Kunhiraman DS, Rajam L (2012) Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J 10:40CrossRefPubMedPubMedCentral Kumar S, Kunhiraman DS, Rajam L (2012) Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J 10:40CrossRefPubMedPubMedCentral
8.
go back to reference Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Seve P (2015) Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res 61:53–62CrossRefPubMed Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Seve P (2015) Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res 61:53–62CrossRefPubMed
9.
go back to reference Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F (2010) Adult-onset Still’s disease. Rheumatol Int 30:855–862CrossRefPubMed Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F (2010) Adult-onset Still’s disease. Rheumatol Int 30:855–862CrossRefPubMed
10.
go back to reference Chen DY, Lan JL, Lin FJ, Hsieh TY (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol 31:2189–2198PubMed Chen DY, Lan JL, Lin FJ, Hsieh TY (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol 31:2189–2198PubMed
11.
go back to reference Han JH, Suh CH, Jung JY, Nam JY, Kwon JE, Yim H, Kim HA (2015) Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still’s disease. Arthritis Res Ther 17:260CrossRefPubMedPubMedCentral Han JH, Suh CH, Jung JY, Nam JY, Kwon JE, Yim H, Kim HA (2015) Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still’s disease. Arthritis Res Ther 17:260CrossRefPubMedPubMedCentral
12.
go back to reference Andersson U, Antoine DJ, Tracey KJ (2014) The functions of HMGB1 depend on molecular localization and post-translational modifications. J Intern Med 276:420–424CrossRefPubMed Andersson U, Antoine DJ, Tracey KJ (2014) The functions of HMGB1 depend on molecular localization and post-translational modifications. J Intern Med 276:420–424CrossRefPubMed
14.
go back to reference Harris HE, Andersson U, Pisetsky DS (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8:195–202CrossRefPubMed Harris HE, Andersson U, Pisetsky DS (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8:195–202CrossRefPubMed
15.
go back to reference Wahamaa H, Schierbeck H, Hreggvidsdottir HS, Palmblad K, Aveberger AC, Andersson U, Harris HE (2011) High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther 13:R136CrossRefPubMedPubMedCentral Wahamaa H, Schierbeck H, Hreggvidsdottir HS, Palmblad K, Aveberger AC, Andersson U, Harris HE (2011) High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther 13:R136CrossRefPubMedPubMedCentral
16.
go back to reference Lu M, Yu S, Xu W, Gao B, Xiong S (2015) HMGB1 promotes systemic lupus erythematosus by enhancing macrophage inflammatory response. J Immunol Res 2015:946748CrossRefPubMedPubMedCentral Lu M, Yu S, Xu W, Gao B, Xiong S (2015) HMGB1 promotes systemic lupus erythematosus by enhancing macrophage inflammatory response. J Immunol Res 2015:946748CrossRefPubMedPubMedCentral
17.
go back to reference Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430PubMed Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430PubMed
18.
go back to reference Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D et al (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70:118–136CrossRef Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D et al (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70:118–136CrossRef
19.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefPubMed Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefPubMed
20.
go back to reference Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRefPubMedPubMedCentral Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRefPubMedPubMedCentral
21.
go back to reference Kim HA, An JM, Nam JY, Jeon JY, Suh CH (2012) Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol 39:1399–1406CrossRefPubMed Kim HA, An JM, Nam JY, Jeon JY, Suh CH (2012) Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol 39:1399–1406CrossRefPubMed
22.
go back to reference Bae CB, Suh CH, An JM, Jung JY, Jeon JY, Nam JY, Kim HA (2014) Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol 41:2403–2408CrossRefPubMed Bae CB, Suh CH, An JM, Jung JY, Jeon JY, Nam JY, Kim HA (2014) Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol 41:2403–2408CrossRefPubMed
23.
go back to reference Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Fruhwald MC, Dassmann S, Pham TH, Roth J et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58:3924–3931CrossRefPubMedPubMedCentral Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Fruhwald MC, Dassmann S, Pham TH, Roth J et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58:3924–3931CrossRefPubMedPubMedCentral
25.
go back to reference Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X, Abraham E (2008) High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 181:4240–4246CrossRefPubMedPubMedCentral Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X, Abraham E (2008) High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 181:4240–4246CrossRefPubMedPubMedCentral
26.
go back to reference Chen Y, Sun W, Gao R, Su Y, Umehara H, Dong L, Gong F (2013) The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology (Oxford) 52:1739–1747CrossRef Chen Y, Sun W, Gao R, Su Y, Umehara H, Dong L, Gong F (2013) The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology (Oxford) 52:1739–1747CrossRef
27.
go back to reference Jiang W, Pisetsky DS (2007) Mechanisms of disease: the role of high-mobility group protein 1 in the pathogenesis of inflammatory arthritis. Nat Clin Pract Rheumatol 3:52–58CrossRefPubMed Jiang W, Pisetsky DS (2007) Mechanisms of disease: the role of high-mobility group protein 1 in the pathogenesis of inflammatory arthritis. Nat Clin Pract Rheumatol 3:52–58CrossRefPubMed
28.
go back to reference Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S et al (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48:971–981CrossRefPubMed Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S et al (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48:971–981CrossRefPubMed
29.
go back to reference Guo HF, Liu SX, Zhang YJ, Liu QJ, Hao J, Gao LX (2011) High mobility group box 1 induces synoviocyte proliferation in rheumatoid arthritis by activating the signal transducer and activator transcription signal pathway. Clin Exp Med 11:65–74CrossRefPubMed Guo HF, Liu SX, Zhang YJ, Liu QJ, Hao J, Gao LX (2011) High mobility group box 1 induces synoviocyte proliferation in rheumatoid arthritis by activating the signal transducer and activator transcription signal pathway. Clin Exp Med 11:65–74CrossRefPubMed
30.
go back to reference Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48:2052–2058CrossRefPubMed Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48:2052–2058CrossRefPubMed
31.
go back to reference Schierbeck H, Pullerits R, Pruunsild C, Fischer M, Holzinger D, Laestadius A, Sundberg E, Harris HE (2013) HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J Rheumatol 40:1604–1613CrossRefPubMed Schierbeck H, Pullerits R, Pruunsild C, Fischer M, Holzinger D, Laestadius A, Sundberg E, Harris HE (2013) HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J Rheumatol 40:1604–1613CrossRefPubMed
32.
go back to reference Bobek D, Grcevic D, Kovacic N, Lukic IK, Jelusic M (2014) The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J 12:50CrossRefPubMedPubMedCentral Bobek D, Grcevic D, Kovacic N, Lukic IK, Jelusic M (2014) The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J 12:50CrossRefPubMedPubMedCentral
33.
go back to reference Chen T, Guo ZP, Li L, Wang L, Jia RZ, Cao N, Qin S, Li MM (2013) Increased HMGB1 serum levels and altered HMGB1 expression in patients with psoriasis vulgaris. Arch Dermatol Res 305:263–267CrossRefPubMed Chen T, Guo ZP, Li L, Wang L, Jia RZ, Cao N, Qin S, Li MM (2013) Increased HMGB1 serum levels and altered HMGB1 expression in patients with psoriasis vulgaris. Arch Dermatol Res 305:263–267CrossRefPubMed
34.
go back to reference Abdulahad DA, Westra J, Reefman E, Zuidersma E, Bijzet J, Limburg PC, Kallenberg CG, Bijl M (2013) High mobility group box1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE). Lupus 22:597–606CrossRefPubMed Abdulahad DA, Westra J, Reefman E, Zuidersma E, Bijzet J, Limburg PC, Kallenberg CG, Bijl M (2013) High mobility group box1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE). Lupus 22:597–606CrossRefPubMed
35.
go back to reference Andersson U, Harris HE (2010) The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 1799:141–148CrossRefPubMed Andersson U, Harris HE (2010) The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 1799:141–148CrossRefPubMed
36.
go back to reference Bae JS (2012) Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch Pharm Res 35:1511–1523CrossRefPubMed Bae JS (2012) Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch Pharm Res 35:1511–1523CrossRefPubMed
37.
go back to reference Goldstein RS (2008) High mobility group box-1 protein as a tumor necrosis factor-independent therapeutic target in rheumatoid arthritis. Arthritis Res Ther 10:111CrossRefPubMedPubMedCentral Goldstein RS (2008) High mobility group box-1 protein as a tumor necrosis factor-independent therapeutic target in rheumatoid arthritis. Arthritis Res Ther 10:111CrossRefPubMedPubMedCentral
Metadata
Title
Elevated high-mobility group B1 levels in active adult-onset Still’s disease associated with systemic score and skin rash
Authors
Ju-Yang Jung
Chang-Hee Suh
Seonghyang Sohn
Jin-Young Nam
Hyoun-Ah Kim
Publication date
01-08-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 8/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3314-x

Other articles of this Issue 8/2016

Clinical Rheumatology 8/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine